Thanks
@Scott th Ratbag,
@Greenwave17. Good stuff.
I wonder about the timeline though. Couldn't IHL42x become shiny enough for acquisition sooner than 4-5 years?
Camargo stated in their independent strategic assessment report dated 25th of March 2020, that it believed commercialisation could be achievable within 2.5 years, as opposed to up to 12 years for the average new drug pathway.
We are now about 8 months behind the schedule envisioned in that document, ostensibly because recruitment for the 2b trial took longer than anticipated... but that would still place the potential for FDA approval application by end of 2022, or early 2023, and a result of that application by perhaps Q3 2023. That's just 2 years from now.
If IHL-42x receives approval from the FDA, and remains well-positioned to displace CPAP use as well as be picked up by the millions of OSA sufferers who have given up on CPAP or had mild enough OSA to not need one, wouldn't offers start coming in pretty much straight away? A relationship may already exist at that point in time, accompanying the process and costs of the phase 3 trials in the USA, in view for an acquisition if all goes smoothly?
I'm not in a huge rush, but I'm curious about how this timeline of about 2 years compares to your thoughts regarding 4-5 years.
.
